Sphingolipids are abundant constituents of neuronal membranes and have been implicated in intracellular signaling. We show that two analogs of glycosphingolipid biosynthetic intermediates, fumonisin B 1 (which inhibits dihydroceramide synthesis) and DL-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) (which inhibits glucosylceramide synthesis) decrease glycosphingolipid synthesis in rat sympathetic neurons. Although both fumonisin and PPMP inhibit glycosphingolipid synthesis, these inhibitors have differential effects on ceramide metabolism in axons. threo-PPMP, but not erythro-PPMP or fumonisin, induces an accumulation of [ 3 H]palmitate-labeled ceramide and impairs axonal growth. Moreover, exogenously added, cell-permeable C 6 -ceramide, but not C 6 -dihydroceramide, mimicks the effect of PPMP. Our studies suggest that the lipid second messenger ceramide acts in distal axons, but not cell bodies, as a negative regulator of neurite growth.
Glycosphingolipids (GSLs) 1 are major components of eukaryotic cell membranes and are particularly enriched in neuronal membranes. Lipids of this class contain one or more sugar residues attached to a sphingoid base backbone. GSLs are present in the outer leaflet of the plasma membrane (1, 2) where they have been postulated to play a role in a number of important cellular processes including cell-cell and cell-substratum recognition, adhesion, differentiation, proliferation, and oncogenic transformation. The pattern of GSLs differs among cell types and changes during development, cellular differentiation, and oncogenic transformation suggesting an important role for GSLs in cell growth and proliferation (3) (4) (5) .
In addition, intermediates in the biosynthesis and catabolism of sphingolipids and GSLs may function as lipid second messengers mediating the effects of extracellular agents and agonists (6 -8) . One approach used extensively to examine the function of GSLs is the exogenous addition of GSLs to cells, since the amphipathic nature of GSLs permits their incorporation into cellular membranes. The enrichment of gangliosides (sialic acid containing GSLs) in neuronal membranes induces neuritogenesis (3, 9 -12) , modulates growth factor receptor activity (reviewed in Refs. 3, 13, 14) , potentiates responses to neurotrophic factors (13, 15) , and protects against apoptotic death caused by withdrawal of trophic support (16) . Moreover, antibodies raised against gangliosides inhibit neurite outgrowth from neural cells and tissues slices in vitro (17, 18) . Tettamanti and Riboni (19) have summarized the role of gangliosides in neurodifferentiation, neuritogenesis, and synaptogenesis.
Only recently has the effect of the reduction of cellular GSL levels on neurons, through the inhibition of endogenous GSL synthesis, been examined. Inhibition of dihydroceramide synthesis, an early step in the synthesis of all GSLs (see Fig. 1 ), in cultured hippocampal neurons disrupts axonal growth (20) and the formation and maintenance of axonal branches (21) . Similar studies have found that sphingolipid biosynthesis is essential for dendrite growth and survival of cerebellar Purkinje cells (22) .
In the present study, we have investigated the role of GSLs in neurite growth using two inhibitors of endogenous GSL synthesis. One inhibitor, fumonisin B 1 (FB 1 ), has been demonstrated to inhibit sphinganine N-acyltransferases ( Fig. 1 ) in a variety of cell types such as rat hepatocytes (23) , LLC-PK 1 pig kidney cells (24) , and hippocampal neurons (20) . The second agent, PPMP (DL-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol), is a potent inhibitor of glucosylceramide synthesis (Fig. 1) . A less active analogue of PPMP, PDMP (DL-1-phenyl-2-decanoylamino-3-morpholinopropanol), blocks GSL synthesis in cultured 3T3 cells (25) , Madin-Darby canine kidney cells (26) , and hippocampal neurons (21) . Although PPMP and PDMP inhibit the synthesis of glucosylceramide in cellular homogenates to a similar extent, PPMP has 10 times the potency of PDMP in intact cells (26) .
We present evidence that both FB 1 and PPMP inhibit GSL synthesis in cultured primary rat sympathetic neurons. Contrary to our initial hypothesis, however, our results suggest that newly synthesized GSLs are not essential for neurite growth but that the lipid second messenger ceramide negatively regulates neurite growth.
EXPERIMENTAL PROCEDURES
Materials- [9,10- 3 H]Palmitate (specific activity 54 Ci/mmol) was purchased from Amersham Canada, Oakville, Ontario, Canada. FB 1 was generously provided by Dr. A. Merrill, Emory University, Atlanta, * This research was supported in part by a grant from the Medical Research Council of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
b Contributed equally to the experimental and theoretical aspects of this research. or purchased from Sigma. threo-PPMP, erythro-PPMP, C 6 -ceramide, and C 6 -dihydroceramide were purchased from Matreya Inc., Pleasant Gap, PA. NBD-C 6 -ceramide was purchased from Molecular Probes, Inc. Eugene, OR. Thin layer chromatography plates and high performance thin layer chromatography plates (silica gel G) were obtained from BDH Chemicals, Edmonton, AB, Canada. Standard phospholipids were either isolated from rat liver or purchased from Avanti Polar Lipids, Birmingham, AL. Ganglioside standards were kindly supplied by Dr. R. Yu, Medical College of Virginia, Richmond, VA. L15 medium without antibiotics was purchased from Life Technologies, Inc. Mouse 2.5S NGF was obtained from Cedarlane Laboratories Ltd. (Hornby, ON, Canada). Rat serum was provided by the University of Alberta Laboratory Animal Services. All other reagents were from Sigma or Fisher.
Preparation of Neuronal Cultures-General procedures for culture of rat sympathetic neurons have been previously described (27) . Briefly, neurons from the superior cervical ganglia of newborn rats (SpragueDawley, supplied by the University of Alberta Farms) were enzymatically and mechanically dissociated and plated at a density of two ganglia/well in collagen-coated 24-well plates. Alternatively, the neurons were plated in the center compartment of compartmented dishes at a density of 0.6 to 0.8 ganglia/dish. The compartmented cultures were constructed as described previously (28) . Collagen-coated 35-mm Falcon tissue culture dishes were scratched so that 20 parallel tracks were formed on the dish surface. A Teflon divider was sealed to the floor of the dish with silicon grease thus partitioning the dish into three compartments. The dissociated neurons were plated in the center compartment. Within 1-2 days neurites elongated along the tracks, penetrated the silicon grease barriers beneath the divider and entered the left and right compartments. L15 medium without antibiotics, but supplemented with the additives prescribed by Hawrot and Patterson (29) , including bicarbonate and methylcellulose, was used as basal culture medium. Medium supplied to the center compartment containing the cell bodies was supplemented with 2.5% rat serum, 1 mg/ml ascorbic acid, 10 M cytosine arabinoside (to prevent growth of non-neuronal cells), and 10 ng/ml NGF. In many experiments delipidated rat serum (30) was used. Medium supplied to the side compartments contained 10 or 100 ng/ml NGF, as indicated. After 6 days, cytosine arabinoside treatment was discontinued, and NGF was confined to the side compartments (31, 32) . Each compartment maintained a separate fluid environment with virtually no flow between compartments (28, 32) . L15 medium supplied to neurons cultured in 24-well dishes was supplemented with 2.5% rat serum, 1 mg/ml ascorbic acid, and 100 ng/ml NGF. Culture medium was changed every 3-6 days. Typically, cells were cultured for 9 -13 days prior to the start of experiments.
Treatment of Neuronal Cultures-FB 1 , erythro-PPMP, and threo-PPMP were dissolved in water to make 10 mM stock solutions. C 6 Ceramide and C 6 -dihydroceramide were dissolved in dimethyl sulfoxide to make 10 mM stock solutions which were used to prepare medium containing the desired final concentration of inhibitor or ceramide. The final concentration of dimethyl sulfoxide in the culture medium of cells treated with C 6 -ceramide or C 6 -dihydroceramide never exceeded 0.25%. Control cultures were given a similar aliquot of dimethyl sulfoxide.
Measurement of de Novo GSL Biosynthesis-The effect of FB 1 and PPMP on GSL synthesis was determined by preincubation of neurons cultured in 24-well dishes in the presence or absence of the indicated concentration of inhibitor for 4 days. [ 3 H]Palmitate (10 Ci/ml) was present during the last 24 h. Radiolabeled medium was aspirated, and neurons were washed twice with ice-cold phosphate-buffered saline (pH 7.4). Cellular material was collected in methanol/water (8:3, v/v) and sonicated for 10 s using a probe sonicator. Chloroform was added to give a final ratio of chloroform/methanol/water of 4:8:3 (v/v). The solvents were evaporated, and gangliosides and phospholipids were extracted with diisopropyl ether/butanol/50 mM NaCl (6:4:5, v/v) as described by Ladisch and Gillard (33) . Under these conditions gangliosides are recovered in the lower aqueous phase. The samples were desalted by passage through a Sephadex G-50 column. Gangliosides were separated, along with authentic standards, by high performance thin layer chromatography in the solvent system chloroform/methanol/15 mM CaCl 2 (55:45:10, v/v). The plates were sprayed with resorcinol-HClCu 2ϩ reagent (34) and heated at 180°C for 20 min. Bands corresponding to authentic standards of G M1 , G M3 , and G T1b were scraped, and radioactive incorporation was measured. The phospholipids PC and SM were separated by thin layer chromatography in the solvent system chloroform/methanol/acetic acid/formic acid/water (35:15:6:2:1, v/v). Bands corresponding to authentic PC and SM were scraped, and radioactivity was measured. Ceramide was separated by thin layer chromatography in two consecutive solvent systems, chloroform/methanol/acetic acid (9:1:1, v/v) followed by petroleum ether/diethyl ether/acetic acid (60:40:1, v/v). The band corresponding to authentic ceramide was scraped, and radioactivity incorporated was measured. In all cases, radioactive incorporation was normalized to total phospholipid mass.
Measurement of Neurite Extension-Neurite extension was measured in compartmented cultures. Neuritotomy was performed by mechanical removal of distal neurites from left and right compartments with a jet of sterile distilled water delivered with a syringe through a 22-gauge needle. The water was aspirated and the wash repeated twice followed by addition of fresh culture medium. This procedure effectively removes all visible traces of neurites from the side compartments (35) . Measurements of neurite growth were made as described previously (35) using a Nikon Diaphot inverted microscope with phase contrast optics outfitted with a MD2 microscope digitizer (Minnesota Datametrics Corp., Minneapolis, MN) which tracks stage movements to an accuracy of Ϯ5 m. An on-line computer using custom software (Minnesota Datametrics Corp.) calculated the distance from the edge of the silicone grease to the farthest extending neurite on each track and combined these measurements to obtain means and standard errors. In each culture, neurites in 16 tracks were measured in left and right compartments.
Metabolism of Fluorescent Ceramide-13-Day-old neurons cultured in compartmented dishes were given 10
in the distal neurite-containing compartment. After 24 h, the medium was aspirated, and neurites were washed three times with icecold phosphate-buffered saline (pH 7.4). Cellular material was collected and lipids extracted (36) and separated by thin layer chromatography using a three-solvent system (37) . Spots corresponding to authentic standards of ceramide, ceramide-1-phosphate, and SM were scraped, extracted from the silica, and quantified using a Hitachi F-2000 fluorimeter.
Other Methods-The phospholipid content of cells was measured by lipid phosphorous determination (38) .
RESULTS

Inhibition of de Novo Sphingolipid Biosynthesis in Sympa-
thetic Neurons-We examined the effects of FB 1 and PPMP on sphingolipid synthesis in rat sympathetic neurons. 11-Day-old neurons, cultured in 24-well dishes, were incubated with various concentrations of FB 1 , threo-PPMP, or erythro-PPMP for 4 days. [ 3 H]Palmitate (10 Ci/ml) was added for the last 1 day of incubation, and incorporation of radiolabel into gangliosides was measured. There was no advantage to using compartmented cultures for this study since when [ 3 H]palmitate is supplied to distal axons the label rapidly equilibrates throughout the neurons. Fig. 2 shows that both FB 1 and threo-PPMP inhibited the incorporation of [ 3 H]palmitate into G M1 in a dosedependent manner. As expected, erythro-PPMP did not reduce the incorporation of [ 3 H]palmitate into G M1 since the erythro isomer does not inhibit sphinganine N-acyltransferase (25) . Table I Glycosphingolipids and Neurite Growth-Since FB 1 and PPMP inhibited GSL synthesis in rat sympathetic neurons, the response of neurite growth to these inhibitors was investigated. Neurons were plated in the center compartment of compartmented culture dishes and allowed to grow for 11 days. At that time, medium containing 5 M PPMP was given to either the center (cell body-containing) compartment alone, or to the side (distal axon-containing) compartments. Control cultures were given medium without PPMP. After 3 days distal neurites were removed from the left and right compartments (neuritotomy/ axotomy), and cells were incubated as before. Neurite extension was measured every day for the following 4 days (Fig. 3) . In cultures that had been given threo-PPMP in the distal axoncontaining compartments alone, 3.7 days after neuritotomy neurite extension was 61% less than that of cultures given medium lacking PPMP (Fig. 3A) . In contrast, growth of neurites of cultures given threo-PPMP to the cell body-containing compartment alone was unaffected, and neurites elongated at the same rate as did untreated cells. The effect of threo-PPMP on neurite growth was most likely specifically related to inhibition of glucosylceramide synthase since the erythro isomer of PPMP did not affect axonal elongation regardless of whether it was added to the cell body-or distal axon-containing compartments (Fig. 3B) . Only in those cultures to which threo-PPMP had been added to the distal axons was neurite growth impaired. The same effect (i.e. inhibition of distal neurite growth) was observed when cultures were treated with threo-PPMP in both center and side compartments at the same time (data not shown).
To exclude a general toxic effect of threo-PPMP on sympathetic neurons, some cultures that had been incubated with threo-PPMP in the distal axon-containing compartments for the first 3 days were given medium lacking the inhibitor after axotomy. Neurite growth resumed at approximately the normal rate (0.7 mm/day for PPMP-treated cultures versus 0.8 mm/day for untreated neurons) indicating that the effect of threo-PPMP on neurite growth was reversible. Moreover, threo-PPMP did not exert a direct cytotoxic effect since, when threo-PPMP was added to the cell body-containing compartment alone, neurites extended at the same rate as in untreated cells (Fig. 3A) . The effect of FB 1 on axonal elongation was also investigated. Sympathetic neurons, cultured for 11 days in compartmented dishes, were given 25 M FB 1 either in the center, cell bodycontaining compartment alone, or in the distal axon-containing compartments alone. After 3 days, cultures were axotomized and given FB 1 in either the side or center compartments, as before. Control cultures were given medium without FB 1 in all compartments. Neurite extension was subsequently measured every 24 h. Axon growth in cultures given FB 1 to the cell body-containing compartment alone (Fig. 4) , to the distal axoncontaining compartments alone (Fig. 4) , or to both compartments (data not shown) was identical to that in control cultures. This result was unexpected since in these neurons 25 M FB 1 inhibited GSL synthesis to a similar extent to that of threo-PPMP (Fig. 2 and Table I ). When cells were treated with a higher concentration of FB 1 (50 M) in the cell body-or distal axon-containing compartments, neurite extension was 28 and 21% less than in control cells, respectively. However, this effect was probably due to cytotoxicity since cells incubated for 3 days in the presence of 50 M FB 1 , and transferred after axotomy to medium containing no FB 1 , did not recover normal axonal growth (data not shown).
Culture medium supplemented with 2.5% rat serum, which may be a source of some sphingolipids (39) , is routinely given to the cell body-containing compartment. Thus, possible explanations for the observed lack of effect of the inhibitors when supplied to the cell body-containing compartment were either that sphingolipids were present in serum or that the inhibitors bound albumin, reducing the effective concentration of FB 1 or PPMP in the medium. Medium containing 1% delipidated rat serum, or medium completely lacking serum, was used to minimize the possible interference of exogenously added lipids. Results obtained under these conditions were identical to those obtained using medium containing 2.5% rat serum, i.e. neurite growth was impaired only in cultures treated with threo-PPMP in distal axons and FB 1 did not affect axonal elongation.
Since threo-PPMP impaired axonal growth, whereas FB 1 did not, we concluded that threo-PPMP is acting on neurite extension via a mechanism other than inhibition of GSL synthesis. In addition, our results suggest that newly synthesized GSLs are not required for axonal growth.
FB 1 Decreases, Whereas PPMP Increases, Labeled Ceramide-The experiments presented in Fig. 2 and Table I demonstrate that both FB 1 and PPMP inhibit GSL synthesis in rat sympathetic neurons. However, because FB 1 and PPMP inhibit different enzymes (Fig. 1) , we would anticipate that the two inhibitors would differentially affect ceramide levels: FB 1 would be expected to decrease the level of ceramide, whereas PPMP treatment would result in ceramide accumulation. In rabbit skin fibroblasts threo-PDMP has been reported to increase the intracellular mass of ceramide (40) . Alternatively, we might expect that PPMP would increase SM levels since threo-PDMP enhances the synthesis of labeled SM and ceramide from [ 3 H]palmitate in 3T3 cells (41) and causes SM accumulation in hippocampal neurons (21) . We therefore investigated the effect of FB 1 and PPMP on the incorporation of [ 3 H]palmitate into SM, ceramide, and PC in rat sympathetic neurons. Neurons were treated for 4 days according to the protocol used in the experiment depicted in Fig. 2. [ 3 H]Palmitate was added during the last 24 h, and radioactivity incorporated into SM, ceramide, and PC was measured. FB 1 treatment decreased the incorporation of [ 3 H]palmitate into SM by ϳ50% (Fig. 5C) . However, neither isomer of PPMP affected the incorporation of radioactivity into SM (Fig. 5D) . Treatment of neurons with FB 1 inhibited the incorporation of [ 3 H]palmitate into ceramide (Fig. 5A) , which might explain the reduced incorporation of radioactivity into SM (Fig. 5C ). On the other hand, (Fig. 5, E and F) .
Exogenously Added Ceramide Inhibits Neurite ExtensionSince threo-PPMP, but not erythro-PPMP or FB 1 , inhibited neurite extension in rat sympathetic neurons (Figs. 3 and 4) , and threo-PPMP elevated labeled ceramide levels within the neurons (Fig. 5) , we considered the possibility that ceramide might be responsible for the growth inhibitory effect of threo-PPMP. If this were the case, pretreatment of neurons with FB 1 might be expected to prevent the accumulation of ceramide that occurred when cells were incubated with threo-PPMP (see Fig. 1 ) and might thereby eliminate the inhibitory effect of threo-PPMP on neurite growth. We tested this hypothesis by incubation of distal axons of 11-day-old neurons with 25 M FB 1 for 4 days, after which the medium was changed, and fresh medium containing both FB 1 (25 M) and threo-PPMP (5 M) was added. After 3 days, distal neurites were axotomized and both inhibitors were supplied to the side compartments for an additional 3 days, after which axon extension was measured. Some cells were given 5 M threo-PPMP without FB 1 both before and after axotomy, and other cells were incubated without FB 1 and threo-PPMP throughout the experiment. In the latter cultures, neurite extension was 2.65 Ϯ 0.04 mm. In cultures provided with threo-PPMP neurite growth was inhibited (extension was 0.93 Ϯ 0.03 mm) as occurred in the experiment depicted in Fig. 3 . However, neurite extension of neurons given both FB 1 and threo-PPMP was very similar to that of neurons incubated without either inhibitor (2.48 Ϯ 0.06 mm). The results of this experiment support the idea that ceramide inhibits axon growth.
As additional evidence that ceramide inhibits neurite extension, we next determined the effect of cell-permeable, shortacyl chain (6 carbons) ceramide (C 6 -ceramide) on neurite extension. Sympathetic neurons were plated in three-compartment dishes and allowed to grow for 14 days, after which 10 M C 6 -ceramide or 10 M erythro-C 6 -dihydroceramide was supplied to either the cell body-containing compartment alone or the distal axon-containing compartments alone. After 2 days the cells were neuritotomized and re-incubated with C 6 -ceramide or erythro-C 6 -dihydroceramide, then neurite extension was measured every day for the following 5 days. Fig. 6A shows that neurons treated with C 6 -ceramide in the cell body-containing compartment alone elongated at the same rate as did untreated cells. On the other hand, treatment of neurons with C 6 -ceramide in the distal axon-containing compartments alone inhibited neurite elongation by ϳ60%. Neurite growth was also inhibited when cultures were treated with C 6 -ceramide simultaneously in all compartments (data not shown). These results correlate with the effect of threo-PPMP on neurite growth (Fig. 3A) , indicating that ceramide might mediate the inhibitory effect of threo-PPMP on axonal growth.
A possible explanation for the observed lack of an effect of ceramide when supplied to the cell body-containing compartment alone was that ceramide might have bound components of serum present in the medium and thereby reduce the effective concentration of available ceramide. To eliminate this possibility we repeated the experiment depicted in Fig. 6 with medium lacking rat serum. Neurite extension 2.5 days after neuritotomy was 2.04 Ϯ 0.04 mm for cells incubated without ceramide and 2.15 Ϯ 0.04 mm for neurons given 10 M ceramide in the cell body-containing compartment, demonstrating that when C 6 -ceramide is given to cell bodies/proximal axons extension of distal axons is unaffected.
Bielawska et al. (42) have previously shown that C 2 -ceramide inhibits the growth of HL-60 human myelocytic leukemia cells and induces apoptosis, whereas erythro-C 2 -dihydroceramide is inactive. We therefore examined the effect of erythro-C 6 -dihydroceramide on neurite growth. Erythro-C 6 -dihydroceramide (10 M) did not inhibit axonal elongation when given to either the cell body-containing compartment or the distal axoncontaining compartments (Fig. 6B) confirming the specificity of the inhibitory effect of C 6 -ceramide on axon elongation.
Dioctanoylglycerol (diC 8 -glycerol) is a cell-permeable analog of diacylglycerol, a known antagonist of the effects of ceramide on viability/apoptosis (7). We therefore determined if diC 8 -glycerol reversed the ceramide-mediated inhibition of neurite growth. Rat sympathetic neurons were plated in compartmented dishes for 13 days. Distal neurites were removed and allowed to regenerate for 1 day, after which the right side compartments were supplied with medium containing either 10 M C 6 -ceramide or 30 M diC 8 -glycerol, or both compounds simultaneously. In all cultures, the left compartment contained neither C 6 -ceramide nor diC 8 -glycerol and acted as a control. Neurite extension was measured immediately before treatment and for 2 days following treatment. Neurites in right side compartments that were given C 6 -ceramide retracted slightly after 24 h and did not resume normal growth (neurite elongation before treatment was 0.83 Ϯ 0.03 mm and 1.8 days after FIG. 6 . C 6 -ceramide inhibits neurite growth when applied to distal neurites but not when applied to cell bodies. Neurons cultured for 13 days in compartmented dishes were either untreated (Ϫ) or treated (ϩ) with 10 M C 6 -ceramide (A) or 10 M erythro-C6-dihydroceramide (B) for 3 days in either the cell body-containing compartment or distal axon-containing compartments. At that time, cultures were neuritotomized and allowed to regenerate under the same conditions as before. Neurite extension was measured at indicated times. Results are means Ϯ S.E. (error bars contained within symbols) of measurements from 80 to 100 tracks for each treatment. The experiment was repeated three times with similar results. treatment was 0.55 Ϯ 0.03 mm). Similar results were obtained in cultures given diC 8 -glycerol together with C 6 -ceramide (neurite elongation before treatment was 0.90 Ϯ 0.03 mm and 1.8 days after treatment was 0.55 Ϯ 0.03 mm). Neurites in the left (control) compartment elongated at a rate of 1.06 Ϯ 0.07 mm/ day. Neurites in right side compartments treated with diC 8 -glycerol alone elongated at the same rate as control neurites. We were unable to assess whether or not higher concentrations of diC 8 -glycerol reversed the inhibitory effect of ceramide on neurite growth because 100 M diC 8 -glycerol inhibited neurite elongation. These observations suggest that mechanisms involved in ceramide-mediated inhibition of neurite growth differ from those involved in ceramide-mediated induction of apoptosis. The experiments also show that ceramide acts rapidly on axonal extension and suggest that the delay in the effect of PPMP is due to the time required for accumulation of ceramide within the neurites. Fig. 7 shows photomicrographs of cultures treated with C 6 -ceramide as in the previous experiment. The bottom panel shows the right side compartment 24 h after treatment with 10 M C 6 -ceramide. The C 6 -ceramide-treated neurites were significantly shorter than were untreated neurons (top panel) and were abnormal in appearance. Cell bodies and proximal neurites in the center compartment appeared normal (center panel). Since cell bodies looked morphologically normal when directly exposed to 10 M C 6 -ceramide (data not shown), we conclude that under the conditions used C 6 -ceramide did not induce apoptosis.
Ceramide Metabolism-To determine whether inhibition of axonal growth by PPMP and C 6 -ceramide was due to ceramide itself or to a metabolite of ceramide, we studied the metabolism of a fluorescent, short chain analogue of ceramide, C 6 -NBDceramide. First, we demonstrated that C 6 -NBD-ceramide exhibited the same growth inhibitory properties as C 6 -ceramide. 14-Day-old sympathetic neurons cultured in compartmented dishes were axotomized and given 10 M C 6 -NBD-ceramide in the right side compartment. The left compartment was given medium lacking ceramide as a control. After 24 h, untreated neurites had elongated by 1.03 Ϯ 0.08 mm, whereas neurites treated with C 6 -NBD-ceramide extended by only 0.30 Ϯ 0.04 mm, indicating that this analogue behaved as did C 6 -ceramide in terms of growth inhibition.
To analyze the metabolism of C 6 -NBD-ceramide in rat sympathetic neurons, 14-day-old neurons were incubated with 10 M C 6 -NBD-ceramide in the distal neurite-containing compartments for 24 h, after which neurites were harvested and lipids extracted and isolated. Of the total cell-associated fluorescence 90.2% was recovered in ceramide, 2.3% was in ceramide 1-phosphate, and 2.0% was in SM, showing that in axons of sympathetic neurons, as in other cell types (21, 43, 44) , short chain ceramide is inefficiently metabolized. It is likely that the small unrecovered percentage of fluorescence is present in the form of glucosylceramide or hexanoate derived from the hydrolysis of ceramide to sphingosine. Most likely, therefore, ceramide itself, rather than one of its metabolites, is responsible for inhibition of neurite growth.
DISCUSSION
Our initial goal was to investigate the role of GSLs in neurite growth. A comparison of the effects of two inhibitors of the endogenous synthesis of GSLs (FB 1 and PPMP) suggests that newly synthesized GSLs are not required for normal neurite elongation, rather the lipid second messenger ceramide negatively regulates neurite growth.
Newly Synthesized GSLs Are Not Essential for Neurite Growth-Both FB 1 and threo-PPMP inhibited the incorporation of [ 3 H]palmitate into several gangliosides in rat sympathetic neurons indicating that these agents inhibited GSL synthesis. Consequently, since only threo-PPMP, but not FB 1 , impaired neurite growth newly synthesized GSLs are not essential for axonal growth. This finding is in accordance with a study of Schwarz et al. (21) in which incubation of hippocampal neurons with FB 1 or PDMP (an analogue of PPMP) dramatically decreased the amount of cell surface gangliosides as early as 24 h after the initiation of treatment. However, no effect on axonal growth was observed at this time or even 48 h after the addition of inhibitor; inhibition of GSL synthesis did not affect the formation of the parent axon during its emergence from the cell body. In hippocampal neurons, the most significant effect of inhibition of GSL synthesis was impairment of formation or stabilization of collateral axonal branches (21) . Furuya et al. (22) observed an aberrant growth of dendrites of Purkinje cells depleted of membrane GSLs by FB 1 treatment, and FB 1 treatment resulted in less complex patterns of dendritic arborization, suggesting a role of GSLs in neurite branching. However, no differences in axonal outgrowth were observed between treated and untreated cultures. Unfortunately, our growth assay does not monitor branching. Nor do our experiments exclude the possibility that chronic inhibition of GSL biosynthesis, leading to depletion of cellular GSLs, would eventually affect axonal growth.
Ceramide Negatively Regulates Neurite Growth-Several lines of evidence from our study imply that the distinct effects of FB 1 and PPMP on neurite growth relate to their differential effects on ceramide metabolism. Treatment of rat sympathetic neurons with FB 1 reduced the incorporation of [ 3 H]palmitate into ceramide (Fig. 5A) , whereas the opposite effect (increased incorporation of [ 3 H]palmitate into ceramide) was observed in threo-PPMP-treated cells (Fig. 5B) . Furthermore, pretreatment of neurons with FB 1 prevented the inhibitory effect of threo-PPMP on neurite growth. In addition, exogenously added cellpermeable ceramide mimicked the effect of threo-PPMP on neurite growth (Fig. 6 ). In light of the potent biological effects of ceramide on cells (reviewed in Refs. 7, 8) , these results imply that ceramide is involved in regulation of neurite growth.
A signal transduction pathway initiated by SM hydrolysis, and leading to generation of the second messenger ceramide, has been proposed (7, 45) . Candidate cellular targets for ceramide include a ceramide-activated protein kinase (46), a ceramide-activated protein phosphatase (47, 48) , and protein kinase C (49) . A number of extracellular agents, including tumor necrosis factor-␣ (50 -52), interferon-␥ (50), and interleukin-1 (53, 54) , activate SM hydrolysis and generate ceramide upon receptor binding. The involvement of this pathway in neuronal signaling is also suggested by the finding that NGF (55), as well as other neurotrophins (56) , rapidly activate SM hydrolysis in cell lines expressing the low affinity neurotrophin receptor, p75 NTR . In actively dividing cells, a growing body of data suggests a role for ceramide in growth suppression and apoptosis (7, 8) . The role of growth factor-induced SM catabolism in post-mitotic neurons, however, has not been elucidated. Our study suggests that ceramide negatively regulates neurite growth. It is clear from studies with compartmented rat sympathetic neurons that regulation of neurite growth in response to NGF involves mechanisms localized to the site of NGF application and does not directly involve mechanisms within the cell body (reviewed in Ref. 57 ). It would be logical, therefore, that factors involved in regulation of neurite growth would act at the site of NGF application. Ceramide is a candidate factor since it inhibits neurite growth of compartmented sympathetic neurons only when applied to distal neurites but not when applied to cell bodies (Fig. 6 ). The specificity of the effect of ceramide on neurite growth is demonstrated by the lack of any effect of dihydroceramide, which differs from ceramide only in the absence of a 4,5-trans-double bond, on neurite growth (Fig. 6 ).
Ito and Horigome (58) have recently demonstrated that cellpermeable ceramide delays the onset of programmed cell death induced by NGF deprivation in cultured rat sympathetic neurons. The authors suggest that NGF may suppress programmed cell death by activation of SM hydrolysis via p75 NTR . Thus, ceramide might be involved in both survival and growth of neurites of sympathetic neurons. A role for the p75 NTR receptor in neuronal survival and axon growth has already been suggested by studies using p75-deficient mice (59 -61) . We speculate that NGF-responsive neurons regulate neurite growth via the cross-talk between signaling pathways induced by trkA and p75 NTR . A mechanism could be envisioned in which, under conditions favoring growth, trkA signaling would be active and would suppress the ability of p75 NTR to mediate SM hydrolysis to ceramide, thus promoting neurite growth. Under conditions where growth arrest and retraction of neurites are required, the activity of trkA would be inhibited leading to induction of SM hydrolysis via p75 NTR and rapid arrest of neurite growth. One model of neuronal path finding suggests growth-promoting and growth-inhibitory signals are interpreted in the growth cone and translated into a directed growth response (62, 63) . The local generation of ceramide may be one inhibitory signal regulating neuronal path finding.
The mechanism by which ceramide suppresses neurite growth remains to be determined. Possibly, downstream targets of ceramide, such as ceramide-activated protein kinase (46) , ceramide-activated protein phosphatase (47, 48) , or protein kinase C (49) are activated. The inability of dioctanoylglycerol to reverse the inhibition of axonal growth caused by ceramide highlights important differences between mechanisms involved in regulation of axonal growth and those governing cell viability and induction of apoptosis since the induction of apoptosis by ceramide is reversed by simultaneous addition of either diacylglycerol or phorbol ester (64) .
Ceramide can be converted into a number of putative bioactive lipids such as sphingosine and ceramide 1-phosphate. It is, therefore, possible that a metabolite of ceramide might be responsible for the effects of ceramide on neurite growth. Indeed, sphingosine suppresses NGF-induced neurite sprouting of PC12 cells (65) . Similarly, treatment of distal neurites, but not cell bodies, of compartmented sympathetic neurons with sphingosine inhibits neurite growth (27) . No effect of ceramide on the neurite growth of sympathetic neurons was observed in the latter study since long chain, non-cell-permeable ceramides were used. Addition of exogenous sphingosine rapidly elevates cellular ceramide levels in A431 cells and Neuro2a cells (66, 67) suggesting that some effects of sphingosine may be mediated by its conversion to ceramide. The reverse reaction, the catabolism of exogenous short chain ceramide to sphingosine, has also been demonstrated in Chinese hamster ovary and MadinDarby canine kidney cells (43, 44) . The time course and quantity, of sphingosine generation from exogenous short chain ceramide, however, suggest that sphingosine is unlikely to mediate the rapid effects of ceramide on cells (42) . Ceramide 1-phosphate is generated via phosphorylation of ceramide by ceramide kinase (68) , and the activity of a calcium-dependent ceramide kinase has been detected in rat brain synaptic vesicles (69) . It is, however, unlikely that ceramide 1-phosphate mediates the effects of ceramide on neurite growth since apparently only ceramide generated from SM hydrolysis, not de novo synthesized ceramide, serves as a substrate for ceramide kinase (70) . Moreover, exogenous C 2 -ceramide is poorly metabolized into C 2 -ceramide phosphate (42) . We have also shown that in axons of rat sympathetic neurons only ϳ2% of cellassociated NBD-C 6 -ceramide was converted into ceramide phosphate. We, therefore, conclude that ceramide itself mediates the inhibition of the growth of neurites of sympathetic neurons.
In summary, we have demonstrated that newly synthesized GSLs are not essential for neurite growth. More importantly, these studies support and strengthen the idea that neurite growth is locally regulated within the neurite itself and strongly suggest that the lipid second messenger, ceramide, negatively regulates neurite growth.
